Existing investor Sinopharm Capital came back for a $57.7m round that will support the progression of the small-molecule drug developer's pipeline.
China-based biopharmaceutical company GenFleet Therapeutics has raised almost RMB400m ($57.7m) in series B funding from investors including Sinopharm Capital, the investment arm of pharmaceutical firm Sinopharm, DealStreetAsia has reported.
Alternative asset manager CDH Investments and the local government-led Shenzhen Capital Group co-led the round, which also featured South China Venture Capital, Panlin Capital, Lake Bleu Capital and HighLight Capital, according to a company statement.
GenFleet is developing small molecule therapeutics for cancer and autoimmune diseases. Its lead drug candidate is…
